Aspire Biopharma Holdings, Inc. (ASBP) Stock
ASBP Key Statistics
About Aspire Biopharma Holdings, Inc.
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.
CEO: Kraig T. Higginson. Company website
ASBP — Frequently Asked Questions
What is the ASBP stock price today?
Aspire Biopharma Holdings, Inc. (ASBP) trades at $5.83, up 3,051.35% on the day, as of Sep 20, 2026 14:59 UTC.
What is Aspire Biopharma Holdings, Inc.'s market cap?
Aspire Biopharma Holdings, Inc. has a market capitalisation of $20.18M, calculated from the live ASBP share price and shares outstanding.
What is the P/E ratio of ASBP?
ASBP has no meaningful price-to-earnings ratio: Aspire Biopharma Holdings, Inc. lost $1.45 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Aspire Biopharma Holdings, Inc. make?
Aspire Biopharma Holdings, Inc. generated revenue of $6,202.00 over the trailing twelve months, which puts the stock at 3,253.55 times sales.
What is the 52-week range for ASBP?
ASBP has traded between $0.12 and $37.50 over the past 52 weeks, and the last price is 84.5% below that high.
Is Aspire Biopharma Holdings, Inc. profitable?
No. Aspire Biopharma Holdings, Inc. is loss-making, with a net margin of -9,999.99% over the trailing twelve months.
What sector is Aspire Biopharma Holdings, Inc. in?
Aspire Biopharma Holdings, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US .
Who is the CEO of Aspire Biopharma Holdings, Inc.?
Kraig T. Higginson is the chief executive of Aspire Biopharma Holdings, Inc., which employs 2 people.
Where can I track ASBP in real time?
QFI Terminal shows ASBP with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See ASBP live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open ASBP in Terminal See plans